TheraRadar
← Back
Data updated: Jul 17, 2026

CLINIGEN

Pharma

CLINIGEN is a pharmaceutical company focused on Oncology.

2007
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

CLINIGEN's Key Drugs

CLINIGEN's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

CLINIGEN's Recent FDA Approvals

New NDA/BLA approvals for CLINIGEN over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

CLINIGEN's Therapeutic Areas

CLINIGEN's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 100%
0 drugs Phase 1: 2

CLINIGEN's Top Competitors

CLINIGEN's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

CLINIGEN Pipeline Snapshot

CLINIGEN has 2 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 2 Phase 1.

0
Phase 3
0
Phase 2
2
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling